Bacterial Vaccines and Therapies - Building a Product Pipeline

点击翻译按钮获取中文摘要

Absynth Biologics has successfully demonstrated an innovative approach for developing newantibacterial vaccines and antibodies. Absynth’s technology identifies proteins, essential forthe life of bacteria that harness the immune system. To date the Company has shown itsapproach can protect against infections caused by a major pathogen Staphylococcus aureus (S.aureus), including antibiotic resistant variety MRSA (Methicillin Resistant S. aureus). TheAbsynth anti-S.aureus vaccine and antibodies are being advanced in pre-clinical development.A central aspect of the Absynth technology is the degree of conservation of these proteinsacross the bacterial kingdom. Consequently the same targets found in S. aureus also arepresent in many other bacterial pathogens. With this proprietary knowledge Absynth canrapidly initiate new vaccine and antibody programmes to develop a product pipeline.The objective of this project is to assess the broader market needs to prevent and treatbacterial infections, addressable by Absynth’s technology. With a clear understanding ofunmet customer/patient needs, market size, drivers, dynamics and competition, Absynth willbe able to select those opportunities to build a pipeline.Resistance to antibiotics in increasing at an alarming rate, driving the need for antibacterialvaccines and antibodies. The market for bacterial vaccines is expected to grow from $3.9billion to $15.5 billion by 2014 and there is growing interest in anti-infective antibodyproducts with only one, Synagis, licensed for use.There currently are no marketed S. aureus vaccines or antibodies and the sales potential isestimated to be >US $2 billion. Many other bacterial infections lack vaccines or antibodiesincluding hospital infections cause by C. difficile, sexually transmitted diseases caused by N.gonorrhoea and community-based infections caused by E. coli. The new opportunities forAbsynth are significant.